We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You may need to tell DVLA if you have malignant melanoma - download the correct form if you need to let them know
Projects granted during 2016 that have a primary purpose of translational and applied research - human cancer.
SaBTO advice and recommendations on the risk of cancer being transmitted by an organ transplant, following a review of the evidence.
Estimated proportion of all malignant cancers where patients first presented as an emergency.
AGIR's ninth report (RCE-19): covers the risk of ionising radiation on the development of solid cancers but excludes leukaemia and lymphoma.
Procedures for reporting, recording and auditing B5 core biopsies for normal or benign surgery.
Cutaneous malignant melanoma and occupational exposure to (natural) UV radiation in pilots and aircrew.
Healthcare professionals should consider the possibility of second primary malignancy in patients treated with lenalidomide.
A pooled analysis has shown an increased rate of new primary malignancies in patients given Xgeva (1-year cumulative incidence 1.1%) compared with those given zoledronic acid (0.6%), when used in the indication of the prevention of skeletal-related events with advanced...
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Quarterly updates to the emergency presentations of cancer data by Public Health England.
Tofacitinib should not be used in patients older than 65 years of age, people who are current or past smokers, or individuals with other cardiovascular (such as diabetes or coronary artery disease) or malignancy risk factors unless there are no...
Healthcare professionals should consider this risk when deciding whether to treat patients with thalidomide monitor for the occurrence of these conditions.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.